At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.
At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.
Your daily dose of the clinical news you may have missed.
The FDA has cleared Eisai and Biogen’s Leqembi Iqlik, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.
Your daily dose of the clinical news you may have missed.
Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.
Based on the FAQ section in the ACC's 2025 Concise Clinical Guidance on vaccination in adults with CVD, this short slideshow also offers recommended answers.
Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.
Your daily dose of the clinical news you may have missed.